Institution
Royal Surrey County Hospital
Healthcare•Guildford, United Kingdom•
About: Royal Surrey County Hospital is a healthcare organization based out in Guildford, United Kingdom. It is known for research contribution in the topics: Cancer & Population. The organization has 2222 authors who have published 3064 publications receiving 86753 citations.
Topics: Cancer, Population, Prostate cancer, Breast cancer, Mammography
Papers published on a yearly basis
Papers
More filters
••
TL;DR: Sparing the parotid glands with IMRT significantly reduces the incidence of xerostomia and leads to recovery of saliva secretion and improvements in associated quality of life, and thus strongly supports a role for IMRT in squamous-cell carcinoma of the head and neck.
Abstract: Summary Background Xerostomia is the most common late side-effect of radiotherapy to the head and neck. Compared with conventional radiotherapy, intensity-modulated radiotherapy (IMRT) can reduce irradiation of the parotid glands. We assessed the hypothesis that parotid-sparing IMRT reduces the incidence of severe xerostomia. Methods We undertook a randomised controlled trial between Jan 21, 2003, and Dec 7, 2007, that compared conventional radiotherapy (control) with parotid-sparing IMRT. We randomly assigned patients with histologically confirmed pharyngeal squamous-cell carcinoma (T1–4, N0–3, M0) at six UK radiotherapy centres between the two radiotherapy techniques (1:1 ratio). A dose of 60 or 65 Gy was prescribed in 30 daily fractions given Monday to Friday. Treatment was not masked. Randomisation was by computer-generated permuted blocks and was stratified by centre and tumour site. Our primary endpoint was the proportion of patients with grade 2 or worse xerostomia at 12 months, as assessed by the Late Effects of Normal Tissue (LENT SOMA) scale. Analyses were done on an intention-to-treat basis, with all patients who had assessments included. Long-term follow-up of patients is ongoing. This study is registered with the International Standard Randomised Controlled Trial register, number ISRCTN48243537. Findings 47 patients were assigned to each treatment arm. Median follow-up was 44·0 months (IQR 30·0–59·7). Six patients from each group died before 12 months and seven patients from the conventional radiotherapy and two from the IMRT group were not assessed at 12 months. At 12 months xerostomia side-effects were reported in 73 of 82 alive patients; grade 2 or worse xerostomia at 12 months was significantly lower in the IMRT group than in the conventional radiotherapy group (25 [74%; 95% CI 56–87] of 34 patients given conventional radiotherapy vs 15 [38%; 23–55] of 39 given IMRT, p=0·0027). The only recorded acute adverse event of grade 2 or worse that differed significantly between the treatment groups was fatigue, which was more prevalent in the IMRT group (18 [41%; 99% CI 23–61] of 44 patients given conventional radiotherapy vs 35 [74%; 55–89] of 47 given IMRT, p=0·0015). At 24 months, grade 2 or worse xerostomia was significantly less common with IMRT than with conventional radiotherapy (20 [83%; 95% CI 63–95] of 24 patients given conventional radiotherapy vs nine [29%; 14–48] of 31 given IMRT; p Interpretation Sparing the parotid glands with IMRT significantly reduces the incidence of xerostomia and leads to recovery of saliva secretion and improvements in associated quality of life, and thus strongly supports a role for IMRT in squamous-cell carcinoma of the head and neck. Funding Cancer Research UK (CRUK/03/005).
1,389 citations
••
Royal Liverpool University Hospital1, University of Liverpool2, Clatterbridge Cancer Centre NHS Foundation Trust3, University of Manchester4, Manchester Royal Infirmary5, The Royal Marsden NHS Foundation Trust6, Weston Park Hospital7, Royal Free Hospital8, St James's University Hospital9, Karolinska Institutet10, Uppsala University11, University of Hamburg12, Royal Surrey County Hospital13, Guy's Hospital14, Hammersmith Hospital15, Beatson West of Scotland Cancer Centre16, Cardiff University17, Queen Elizabeth Hospital Birmingham18, Churchill Hospital19, Derriford Hospital20, University Hospital Coventry21, Heidelberg University22
TL;DR: The adjuvant combination of gem citabine and capecitabine should be the new standard of care following resection for pancreatic ductal adenocarcinoma.
1,378 citations
••
University College London1, Francis Crick Institute2, Natera3, University of Leicester4, Harvard University5, Brigham and Women's Hospital6, Institute of Cancer Research7, The Royal Marsden NHS Foundation Trust8, University of Manchester9, University of Birmingham10, University of Aberdeen11, Glenfield Hospital12, Middlesex University13, Royal Free Hospital14, Princess Alexandra Hospital15, Royal Surrey County Hospital16, Ashford University17, Cardiff University18, University Hospital of Wales19, Whittington Hospital20, Boston Children's Hospital21, Semmelweis University22, Technical University of Denmark23, Max Delbrück Center for Molecular Medicine24, Katholieke Universiteit Leuven25
TL;DR: It is shown that phylogenetic ct DNA profiling tracks the subclonal nature of lung cancer relapse and metastasis, providing a new approach for ctDNA-driven therapeutic studies.
Abstract: The early detection of relapse following primary surgery for non-small-cell lung cancer and the characterization of emerging subclones, which seed metastatic sites, might offer new therapeutic approaches for limiting tumour recurrence. The ability to track the evolutionary dynamics of early-stage lung cancer non-invasively in circulating tumour DNA (ctDNA) has not yet been demonstrated. Here we use a tumour-specific phylogenetic approach to profile the ctDNA of the first 100 TRACERx (Tracking Non-Small-Cell Lung Cancer Evolution Through Therapy (Rx)) study participants, including one patient who was also recruited to the PEACE (Posthumous Evaluation of Advanced Cancer Environment) post-mortem study. We identify independent predictors of ctDNA release and analyse the tumour-volume detection limit. Through blinded profiling of postoperative plasma, we observe evidence of adjuvant chemotherapy resistance and identify patients who are very likely to experience recurrence of their lung cancer. Finally, we show that phylogenetic ctDNA profiling tracks the subclonal nature of lung cancer relapse and metastasis, providing a new approach for ctDNA-driven therapeutic studies.
1,179 citations
••
Charles University in Prague1, Pierre-and-Marie-Curie University2, Medical University of Graz3, European Association of Urology4, University of Regensburg5, Queen Alexandra Hospital6, Netherlands Cancer Institute7, Royal Surrey County Hospital8, Autonomous University of Barcelona9, Medical University of Vienna10
TL;DR: The European Association of Urology (EAU) Guidelines Panel on Upper Urinary Tract Urothelial Carcinoma (UTUC) as mentioned in this paper provided updated guidelines to aid clinicians in the current evidence-based management of UTUC and to incorporate recommendations into clinical practice.
1,161 citations
••
TL;DR: In women with stage III or IV ovarian cancer, survival with primary chemotherapy is non-inferior to primary surgery, and giving primary chemotherapy before surgery is an acceptable standard of care for women with advanced ovarian cancer.
948 citations
Authors
Showing all 2225 results
Name | H-index | Papers | Citations |
---|---|---|---|
Aroon D. Hingorani | 111 | 428 | 59171 |
Stephen W. Duffy | 95 | 630 | 38987 |
Stanley W. Ashley | 83 | 498 | 29893 |
Sarah C. Darby | 77 | 244 | 57679 |
Justin Stebbing | 68 | 633 | 18697 |
Susan Lightman | 63 | 401 | 14065 |
Stephen Taylor | 62 | 549 | 16906 |
Edward Chow | 59 | 512 | 14303 |
Hardev Pandha | 57 | 349 | 11617 |
Gordon A. Ferns | 55 | 726 | 14744 |
Vincent Marks | 52 | 332 | 10947 |
Gary Middleton | 47 | 161 | 12552 |
David Russell-Jones | 47 | 154 | 7101 |
David E. Ward | 47 | 236 | 7934 |
Martin G. Cook | 40 | 108 | 5237 |